CN107921025A - 用于治疗纤维症的短链脱氢酶活性的抑制剂 - Google Patents

用于治疗纤维症的短链脱氢酶活性的抑制剂 Download PDF

Info

Publication number
CN107921025A
CN107921025A CN201680026631.8A CN201680026631A CN107921025A CN 107921025 A CN107921025 A CN 107921025A CN 201680026631 A CN201680026631 A CN 201680026631A CN 107921025 A CN107921025 A CN 107921025A
Authority
CN
China
Prior art keywords
alkyl
aryl
group
substituted
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680026631.8A
Other languages
English (en)
Chinese (zh)
Inventor
S·马科维茨
S·格尔森
A·德赛
W·J·浩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
Original Assignee
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University filed Critical Case Western Reserve University
Priority to CN202311729746.1A priority Critical patent/CN118059093A/zh
Publication of CN107921025A publication Critical patent/CN107921025A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680026631.8A 2015-03-08 2016-03-08 用于治疗纤维症的短链脱氢酶活性的抑制剂 Pending CN107921025A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311729746.1A CN118059093A (zh) 2015-03-08 2016-03-08 用于治疗纤维症的短链脱氢酶活性的抑制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562129885P 2015-03-08 2015-03-08
US62/129,885 2015-03-08
PCT/US2016/021374 WO2016144958A1 (en) 2015-03-08 2016-03-08 Inhibitors of short-chain dehydrogenase activity for treating fibrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311729746.1A Division CN118059093A (zh) 2015-03-08 2016-03-08 用于治疗纤维症的短链脱氢酶活性的抑制剂

Publications (1)

Publication Number Publication Date
CN107921025A true CN107921025A (zh) 2018-04-17

Family

ID=56879350

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680026631.8A Pending CN107921025A (zh) 2015-03-08 2016-03-08 用于治疗纤维症的短链脱氢酶活性的抑制剂
CN202311729746.1A Pending CN118059093A (zh) 2015-03-08 2016-03-08 用于治疗纤维症的短链脱氢酶活性的抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311729746.1A Pending CN118059093A (zh) 2015-03-08 2016-03-08 用于治疗纤维症的短链脱氢酶活性的抑制剂

Country Status (8)

Country Link
US (3) US10945998B2 (https=)
EP (1) EP3267995B1 (https=)
JP (3) JP2018511581A (https=)
CN (2) CN107921025A (https=)
AU (3) AU2016229918B2 (https=)
CA (1) CA2979203A1 (https=)
HK (1) HK1250636A1 (https=)
WO (1) WO2016144958A1 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114875003A (zh) * 2022-04-06 2022-08-09 浙江大学 一种短链脱氢酶的突变体、编码基因及编码基因获得方法、突变体的应用
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
CN116507626A (zh) * 2020-05-20 2023-07-28 罗迪奥治疗公司 调节短链脱氢酶活性的组合物和方法
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
WO2024104317A1 (zh) * 2022-11-14 2024-05-23 武汉人福创新药物研发中心有限公司 抑制15-pgdh的化合物及其用途
WO2024169790A1 (zh) * 2023-02-17 2024-08-22 武汉人福创新药物研发中心有限公司 亚砜类化合物及其用途
US12336982B2 (en) 2018-11-21 2025-06-24 Rodeo Therapeutics Corporation Compositions and methods of modulating short-chain dehydrogenase activity
US12616681B2 (en) 2022-08-22 2026-05-05 Case Western Reserve University Compositions and methods for treating renal injury

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2838533T3 (da) 2012-04-16 2017-11-27 Univ Case Western Reserve Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet
US9801863B2 (en) 2012-04-16 2017-10-31 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
AU2014342811B2 (en) 2013-10-15 2019-01-03 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
CN107921025A (zh) 2015-03-08 2018-04-17 卡斯西部储备大学 用于治疗纤维症的短链脱氢酶活性的抑制剂
AU2016248080A1 (en) * 2015-04-14 2017-11-02 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
WO2018187810A1 (en) 2017-04-07 2018-10-11 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating coronary disorders
US20210317132A1 (en) * 2017-05-26 2021-10-14 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
TWI834795B (zh) 2019-01-08 2024-03-11 日商杏林製藥股份有限公司 15-pgdh抑制劑
EP3917911A1 (en) 2019-01-31 2021-12-08 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitors
KR20220146458A (ko) 2020-01-23 2022-11-01 마이오포르테 테라퓨틱스 인코포레이티드 Pgdh 억제제 및 그의 제조 및 사용 방법
JP2023515081A (ja) * 2020-02-21 2023-04-12 ケース ウエスタン リザーブ ユニバーシティ 腎損傷を治療するための組成物および方法
EP4164638A4 (en) * 2020-06-11 2024-06-19 The Board of Trustees of the Leland Stanford Junior University REJUVENATION OF AGED TISSUES AND ORGANS BY INHIBITION OF THE DEGRADING ENZYME PGE2, 15-PGDH
WO2022082009A1 (en) * 2020-10-15 2022-04-21 Epirium Bio Inc. Inhaled formulations of pgdh inhibitors and methods of use thereof
US20250002919A1 (en) * 2021-10-27 2025-01-02 The Board Of Trustees Of The Leland Stanford Junior University Regeneration or rejuvenation of tissues and organs
CN121772923A (zh) * 2023-06-28 2026-03-31 埃皮里姆生物股份有限公司 用于治疗与升高的15-pgdh相关的病况的间歇给药方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013158649A1 (en) * 2012-04-16 2013-10-24 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
WO2013180336A1 (ko) * 2012-05-30 2013-12-05 조선대학교 산학협력단 15-히드록시프로타글란딘 디히드로게나제 및 ｐｇｅ2 활성을 조절하는 황칠나무 추출물의 용도
WO2014160947A1 (en) * 2013-03-29 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Dimethylarginine dimethylaminohydrolase inhibitors and methods of use thereof
WO2015065716A1 (en) * 2013-10-15 2015-05-07 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8405924L (sv) 1984-11-23 1986-05-24 Pharmacia Ab Nya azoforeningar
GB8709248D0 (en) 1987-04-16 1987-05-20 Wyeth John & Brother Ltd Azo compounds
US5445164A (en) 1993-05-11 1995-08-29 Gynetech, Inc. Cervical tissue sampling device
SE9303444D0 (sv) 1993-10-20 1993-10-20 Kabi Pharmacia Ab New use of prostaglandins
US6080772A (en) * 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
US6281227B1 (en) 1996-12-13 2001-08-28 Aventis Pharma Deutschland Gmbh Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
EP1021179B1 (en) 1997-02-04 2004-05-12 Murray A. Johnstone Method of enhancing hair growth
US6214533B1 (en) 1998-04-10 2001-04-10 Konica Corporation Thermally developable photosensitive material
US8068897B1 (en) 1999-03-01 2011-11-29 Gazdzinski Robert F Endoscopic smart probe and method
CN1304318A (zh) 1999-03-16 2001-07-18 东丽株式会社 前列腺素ep4受体作用药和治疗方法
AU7360700A (en) 1999-09-09 2001-04-10 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders
US7004913B1 (en) 2001-05-04 2006-02-28 Cdx Laboratories, Inc. Retractable brush for use with endoscope for brush biopsy
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
EP1558252B1 (en) 2002-08-02 2007-10-10 Merck & Co., Inc. Substituted furo [2,3-b]pyridine derivatives
FR2845000B1 (fr) 2002-09-27 2005-05-27 Oreal Utilisation d'un compose heterocyclique ou de l'un de ses sels pour stimuler ou induire la pousse des cheveux et/ou freiner leur chute
EP1594438B1 (fr) 2003-02-12 2013-07-17 L'Oréal Utilisation d'un inhibiteur de 15-hydroxy prostaglandine déshydrogénase pour favoriser la pigmentation de la peau ou des phanères
NZ546044A (en) * 2003-08-29 2009-09-25 Vernalis Cambridge Ltd Pyrimidothiophene compounds
JP2005325099A (ja) 2004-04-12 2005-11-24 Sankyo Co Ltd チエノピリジン誘導体
WO2006019832A1 (en) * 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating hepatitis c
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
US20090118337A1 (en) * 2005-06-03 2009-05-07 Davis Pamela B Methods and compositions for treating inflammation
US20070071699A1 (en) 2005-06-28 2007-03-29 L'oreal Benzylidene-1,3-thiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting their depigmentation and/or whitening
US20070078175A1 (en) 2005-10-05 2007-04-05 L'oreal Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof
ATE479690T1 (de) 2005-12-20 2010-09-15 Richter Gedeon Nyrt Thienoä2,3-büpyridin derivate
TW200801012A (en) 2006-04-26 2008-01-01 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
CN101970002B (zh) 2007-08-27 2016-05-18 诺福麦德治疗学股份有限公司 用因子Bb特异性抗体抑制补体活化的方法
DE102007049451A1 (de) 2007-10-16 2009-04-23 Merck Patent Gmbh 5-Cyano-thienopyridine
CN101977619B (zh) * 2008-02-15 2013-06-05 诺沃百欧公司 姜黄素的可溶性复合物
US7629112B1 (en) 2008-05-30 2009-12-08 Eastman Kodak Company Color photographic materials with yellow minimum density colorants
US20100093764A1 (en) 2008-10-13 2010-04-15 Devraj Chakravarty AMINES AND SULFOXIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
KR101172638B1 (ko) 2008-12-30 2012-08-08 조선대학교산학협력단 신규한 티아졸리딘디온 유도체 및 그의 용도
EP2308883A1 (en) 2009-10-05 2011-04-13 Centre National De La Recherche Scientifique New derivatives of thieno[2,3-b]pyridine and 5,6,7,8 tetrahydrothieno[2,3 b]quinoline in particular useful in the treatment of malaria
JP6220791B2 (ja) 2011-12-02 2017-10-25 フェイト セラピューティクス，インコーポレイテッド 増強された幹細胞組成物
AU2013202373B2 (en) * 2012-01-25 2016-04-14 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US9801863B2 (en) 2012-04-16 2017-10-31 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
EA034860B1 (ru) 2013-07-10 2020-03-30 РИВАЙВ ЭЛЕКТРОНИКС, ЭлЭлСи Аппараты и способы для управления электропитанием электронных устройств
GB201502020D0 (en) * 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
CN107921025A (zh) 2015-03-08 2018-04-17 卡斯西部储备大学 用于治疗纤维症的短链脱氢酶活性的抑制剂
AU2016248080A1 (en) 2015-04-14 2017-11-02 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
US20190275014A1 (en) 2016-07-18 2019-09-12 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for promoting neurogenesis and inhibiting cell death
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
JP2020514323A (ja) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物と方法
WO2018187810A1 (en) 2017-04-07 2018-10-11 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating coronary disorders
JP2021134242A (ja) 2020-02-25 2021-09-13 株式会社アイティー技研 鉱物油精製方法及び装置
JP7574640B2 (ja) 2020-12-23 2024-10-29 株式会社リコー 画像処理装置、画像処理システム、方法およびプログラム

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013158649A1 (en) * 2012-04-16 2013-10-24 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
WO2013180336A1 (ko) * 2012-05-30 2013-12-05 조선대학교 산학협력단 15-히드록시프로타글란딘 디히드로게나제 및 ｐｇｅ2 활성을 조절하는 황칠나무 추출물의 용도
WO2014160947A1 (en) * 2013-03-29 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Dimethylarginine dimethylaminohydrolase inhibitors and methods of use thereof
WO2015065716A1 (en) * 2013-10-15 2015-05-07 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
US12336982B2 (en) 2018-11-21 2025-06-24 Rodeo Therapeutics Corporation Compositions and methods of modulating short-chain dehydrogenase activity
CN116507626A (zh) * 2020-05-20 2023-07-28 罗迪奥治疗公司 调节短链脱氢酶活性的组合物和方法
CN114875003A (zh) * 2022-04-06 2022-08-09 浙江大学 一种短链脱氢酶的突变体、编码基因及编码基因获得方法、突变体的应用
CN114875003B (zh) * 2022-04-06 2024-05-24 浙江大学 一种短链脱氢酶的突变体、编码基因及编码基因获得方法、突变体的应用
US12616681B2 (en) 2022-08-22 2026-05-05 Case Western Reserve University Compositions and methods for treating renal injury
WO2024104317A1 (zh) * 2022-11-14 2024-05-23 武汉人福创新药物研发中心有限公司 抑制15-pgdh的化合物及其用途
WO2024169790A1 (zh) * 2023-02-17 2024-08-22 武汉人福创新药物研发中心有限公司 亚砜类化合物及其用途

Also Published As

Publication number Publication date
CN118059093A (zh) 2024-05-24
AU2021200610B2 (en) 2022-09-15
CA2979203A1 (en) 2016-09-15
WO2016144958A1 (en) 2016-09-15
AU2016229918B2 (en) 2020-10-29
AU2016229918A1 (en) 2017-09-28
US10945998B2 (en) 2021-03-16
HK1250636A1 (zh) 2019-01-11
JP2023103379A (ja) 2023-07-26
US20180064694A1 (en) 2018-03-08
EP3267995A1 (en) 2018-01-17
EP3267995B1 (en) 2025-10-08
US20210283113A1 (en) 2021-09-16
AU2021200610A1 (en) 2021-03-04
AU2022287625A1 (en) 2023-02-02
EP3267995A4 (en) 2019-02-27
JP7282067B2 (ja) 2023-05-26
JP2018511581A (ja) 2018-04-26
US20250295640A1 (en) 2025-09-25
JP2021038247A (ja) 2021-03-11

Similar Documents

Publication Publication Date Title
CN107921025A (zh) 用于治疗纤维症的短链脱氢酶活性的抑制剂
JP2018511581A5 (https=)
JP6789542B2 (ja) 短鎖デヒドロゲナーゼ活性を調節する組成物および方法
CN110582277B (zh) 用于促进神经发生并抑制神经细胞死亡的短链脱氢酶活性的抑制剂
JP6203820B2 (ja) １５−ｐｇｄｈ活性を調節する組成物および方法
CN108012528A (zh) 调控短链脱氢酶活性的组合物和方法
TWI898100B (zh) 一種新型吡嗪結構fxr促效劑、製備方法及應用
JPH09504777A (ja) ロイコトリエンアンタゴニストとしてのキノリン誘導体
WO2014194209A1 (en) Substituted cyclopentenes as therapeutic agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1250636

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20180417

RJ01 Rejection of invention patent application after publication